Joseph Cherabie

Dr. Joseph Cherabie

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
JCJoseph Cherabie
Joseph Cherabie
PMPatrick Mazi
Patrick Mazi
ARAdriana M. Rauseo
Adriana M. Rauseo
CAChapelle Ayres
Chapelle Ayres
LLLindsey Larson
Lindsey Larson
ASAndrej Spec
Andrej Spec
Histoplasmosis is a common opportunistic infection in people with HIV (PWH); however, no study has looked at factors associated with the long-term mortality of histoplasmosis in PWH. We conducted a single-center retrospective study on the long-term mortality of PWH diagnosed with histoplasmosis between 2002 and 2017. Patients were categorized into three groups based on length of survival after diagnosis: early mortality (death < 90 days), late mortality (death ≥ 90 days), and long-term survivors. Patients diagnosed during or after 2008 were considered part of the modern antiretroviral therapy (ART) era. Insurance type (private vs. public) was a surrogate indicator of socioeconomic status. Out of 54 PWH infected with histoplasmosis, overall mortality was 37%; 14.8% early mortality and 22.2% late mortality. There was no statistically significant difference in survival based on the availability of modern ART (p = 0.60). Insurance status reached statistical significance with 38% of survivors having private insurance versus only 8% having private insurance in the late mortality group (p = 0.05). High mortality persists despite the advent of modern ART, implicating a contribution from social determinants of health, such as private insurance. Larger studies are needed to elucidate the role of these factors in the mortality of PWH.

15 May 2026 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
AHAniruddha Hazra
Aniruddha Hazra
PCPhilip A Chan
Philip A Chan
Meredith ClementMeredith Clement
Meredith Clement
CKChristopher J Kaperak
Christopher J Kaperak
HSHussein Safa
Hussein Safa
RPRupa R Patel
Rupa R Patel
Lenacapavir preexposure prophylaxis (PrEP) implementation across 17 US sites ( ampa#thinsp;= 501) was characterized by delays in initiation driven by payer processes. Early nonpersistence was uncommon (3.6%) but exceeded clinical trial discontinuation rates and was strongly associated with abdominal injections and injection-site reactions requiring clinical contact, underscoring modifiable barriers to early persistence.

3 July 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
JCJoseph Cherabie
Joseph Cherabie

22 August 2026 in Sexually Transmitted Diseases
Verified
Journal Article
Closed access
JCJoseph Cherabie
Joseph Cherabie
GWGermysha Weatherall
Germysha Weatherall
PKPatrick Kojima
Patrick Kojima
CBCaleb Bender
Caleb Bender
DHDonald Hong
Donald Hong
HRHilary Reno
Hilary Reno
Background: Studies have shown that intramuscular benzathine penicillin G (BPG) or bicillin injections cause severe pain in many patients, which may reduce adherence. Local anesthetics mixed with BPG may reduce injection pain without affecting drug effectiveness. The objective of this study was to examine if there is any benefit of adding 0.5 mL 1% lidocaine to prepackaged BPG, with respect to pain, compared with standard of care, in the treatment of Treponema pallidum infections, both 10 min and 24 h after injection. Methods: This study is a double-blinded randomized placebo-controlled trial of the effect on pain of the addition of 0.5 mL 1% lidocaine solution to a prepackaged BPG injection, compared with the addition of 0.5 mL normal saline solution, in adults being treated for syphilis ( T. pallidum ) infections, within the Infectious Diseases Clinic at Washington University in St. Louis, MO. Results: Preliminary analysis included 15 participants. A Wilcoxon signed-rank test indicated a statistically significant reduction in pain 10 min after lidocaine injection compared with the saline injection ( z = −2.65, P = 0.008). The mean pain score following administration, after 10 min, of the lidocaine solution was 3, compared with 6.73 for the saline solution. Overall, 87% of participants reported at least a 2-point reduction in pain scores after 10 min with lidocaine relative to saline. However, no significant difference in pain scores was observed between the 2 solutions at the 24-h follow-up. Conclusion: This trial demonstrates that lidocaine can help reduce the pain associated with intramuscular injections of BPG.